Alicia Okines
Royal Marsden NHS Foundation Trust · The Royal Marsden Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alicia Okines as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:49 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04920708 · Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionRoyal Marsden NHS Foundation Trust · active not recruiting · Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer · principal investigator
- Ph1NCT04360941 · PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerRoyal Marsden NHS Foundation Trust · active not recruiting · Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:49 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.N Engl J Med · 20201,043 citationsRCR 46.1
- 458 citationsRCR 17.8
- 192 citationsRCR 12.5
- 185 citationsRCR 15.1
- Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.Ann Oncol · 201375 citationsRCR 2.2
- 27 citationsRCR 13.5
- Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.Nat Med · 202522 citationsRCR 4.1
- Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.Breast Cancer Res Treat · 20225 citationsRCR 0.3
- 5 citationsRCR 2.5